Elevar Therapeutics

CompanyUnited States

Elevar Therapeutics develops 2 assets, the furthest approved (lirafugratinib in bile duct cancer). Mostly small molecule acting on FGFR2 and KDR; based in the United States.

2
Assets
Furthest stage: Approved; 0
Trials: 1
Signal

Pipeline

2

lirafugratinib
Selectively inhibits FGFR2 signaling to suppress tumor growth.
Approved, Small molecule, FGFR2, bile duct cancer
rivoceranib
Inhibits VEGFR2 signaling to suppress tumor angiogenesis.
Stage not known, Small molecule, KDR

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms2
Signals1
Similar companies6